29/05/2026
On 18th May Design Therapeutics provided an update on their Phase 1/2 RESTORE-FA trial which is taking place in Australia assessing the safety and effectiveness of DT-216P2 in treating FA. The press release provides updates on findings after 4 people took a specific dose of the drug for 4 weeks where they found improvements in clinical measures and dose dependent increases in frataxin mRNA in blood and muscle, with the drug being generally well tolerated. Click this link to for more information: https://www.ataxia.org.uk/research-news/first-fa-patient-dosed-in-restore-fa-trial/